- Home
- MNOV vs TVGN Comparison
MNOV vs TVGN Comparison
Compare MNOV & TVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MNOV | TVGN |
|---|---|---|
| Founded | 2000 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.4M | 63.9M |
| IPO Year | 2004 | N/A |
Fundamental Metrics
Financial Performance| Metric | MNOV | TVGN |
|---|---|---|
| Price | $1.35 | $7.82 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 1 |
| Target Price | ★ $7.50 | N/A |
| AVG Volume (30 Days) | 21.0K | ★ 33.0K |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,360,807.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $180.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 194.15 | N/A |
| 52 Week Low | $1.17 | $0.14 |
| 52 Week High | $1.96 | $12.00 |
Technical Indicators
Market Signals| Indicator | MNOV | TVGN |
|---|---|---|
| Relative Strength Index (RSI) | 45.49 | 49.20 |
| Support Level | $1.35 | $6.41 |
| Resistance Level | $1.43 | $10.08 |
| Average True Range (ATR) | 0.03 | 1.76 |
| MACD | -0.00 | -0.22 |
| Stochastic Oscillator | 43.33 | 27.44 |
Price Performance
Historical ComparisonAbout MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.
About TVGN Tevogen Bio Holdings Inc.
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.